![]() |
|
|
Vol. 300, Issue 1, 112-117, January 2002
Department of Anesthesia, Royal Victoria Hospital, McGill
University, Montreal, Quebec, Canada (A.D., S.B.B., G.P., P.F., D.C.);
and Department of Neurology, The Ohio State University, Columbus, Ohio
(V.N.).
Edrophonium, an anticholinesterase, exerts a biphasic effect on
cardiovascular autonomic drive in humans (lower doses enhance; higher
doses reduce). Twenty-five anesthetized, mechanically respired (10 breaths · min
1, constant tidal volume) patients were
given either saline (n = 10) or edrophonium
(0.01-1.0 mg · kg
1, n = 15)
following surgery. ECG, radial arterial pressure, and respiratory rate
were sampled at 250 Hz to obtain time series for consecutive R-R
intervals (RRIs), and systolic (SBP) and diastolic blood pressure
(DBP). A Wigner distribution was used for time frequency mapping of
spectral powers at high (HFP, 0.15-0.5 Hz) and low (LFP, 0.0-0.05 Hz)
frequency. Edrophonium produced a dose-dependent decrease in heart
rate [baseline 66.8 ± 1.9 (S.E.M.) beats per minute;
maximum decrease to 55.8 ± 1.4 beats per minute with 1.0 mg · kg
1, P < 0.01]. HFP of the
RRI increased at low doses (0.2-0.4 mg · kg
1;
maximum increase to 111.0 ± 58.2% baseline;
P < 0.01) but decreased (
49.5 ± 35.5%
baseline; P < 0.01) at higher (1.0 mg · kg
1) doses. Edrophonium had no effect on SBP and
DBP. HFP of SBP decreased with increasing doses (maximal decrease to
26.2 ± 7.5% baseline, P < 0.01, 1.0 mg · kg
1). LFP of SBP was also decreased (
46.3 ± 10.9% baseline, P < 0.01, 1.0 mg · kg
1). Edrophonium may enhance (lower dose) or
reduce (higher dose) cardiovascular autonomic drive in humans, as
evidenced by the significant changes it evokes in HFP of the RRI
(parasympathetic drive), and in the HFP and LFP of SBP (sympathetic
drive). These observations may account for the modest autonomic side
effects of edrophonium when this drug is used clinically.